P/0366/2017

  • Email
  • Help

Overview

Product details for -
Invented name-
Active substance

Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody

Decision numberEMEA-002197-PIP01-17
PIP numberP/0366/2017
Pharmaceutical form(s)Concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of ocular melanoma

Route(s) of administrationIntravenous use
PIP applicant

Immunocore Ltd
Tel. +1 2153139618
E-mail: Chris.Coughlin@immunocore.com

Decision typeW: decision granting a waiver in all age groups for all conditions/indications

Decision